Roger Ebert, one of America's best known film critics, has not been able to speak since he had emergency cancer surgery on July 1 to repair a burst blood vessel near the site of his June 16 surgery to remove a cancerous growth on his salivary gland. But he can still give a thumbs up or thumbs down as he reviews movies on his Web site.

Starting today, clips from Ebert & Roeper and Ebert's prior episodes of his movie review TV show will be posted here. It just may be the largest collection ever of video-based online movie reviews -- 5,000 movie reviews spanning the past 20 years will be featured.

Ebert is not quite sure when he might return to television as he awaits another surgery to restore his voice. In the meantime, he screens as many as three films a day. He watches DVDs at night to catch up on those he missed, and he's writing more than ever, he says.

In a trendy dash for style, we welcome the newest blog to the network -- StyleDash. Whether your interests lean towards fashion, food or home decorating, StyleDash bloggers are talking about it.

StyleDash features retro to cutting edge trends in accessories, coiffure, cosmetics, eyewear, home style, jewelry, soaps & salves, foods and much more. It's a place. An event. A state of mind. An attitude.

And as every perfect host knows, when you invite a guest, you have graciously prepared something special to greet them on their arrival.

StyleDash is the perfect host. Enter a contest to win a designer handbag or book tote -- just for showing up! What are you waiting for? Have some fun, discover cool, or just read trend buzz -- it's all good. We will be right here when you get back. Promise.

Back in June, Roger Ebert, a three-time thyroid cancer survivor, underwent surgery to remove a cancerous growth on his salivary gland. In July, due to complications from the surgery, he was admitted again into the hospital when a blood vessel burst. Surgeons performed a life-saving emergency procedure to correct the complication. Reports at that time indicated Ebert was in serious but stable condition.

Ebert continues to recover in the hospital. Recently, he explained that the blood vessel rupture was due to breakdown of tissue near the artery as a result of aggressive and intense radiation treatments, called neutron beam radiation, three years ago. He is working to strengthen his vocal cords.

In June, when Ebert, who is 63, first went in for surgery, he said, "This is not considered to be a life-threatening form of cancer, and I expect to make a full recovery. I'll continue to function as a film critic during this time." With this recent explanation on how his recovery is progressing, he said, "I don't have a crystal ball, so I can't tell you when, but I sure look forward to being back on the movie beat,'' and he wanted all his fans to know that he is grateful for the good wishes and support.

For more information and related posts:
Roger Ebert: movie critic cancer survivor battling cancer again
Roger Ebert: suffers serious cancer surgery setback
Jay Leno thumbs up as guest host for Roger Ebert

Herceptin -- a targeted breast cancer drug used to treat women who are Her2 positive -- has received rave reviews and has shown great promise in cutting down on recurrence of this aggressive form of breast cancer. Given over the course of 52 weeks, Herceptin is wondrous for its lack of short-term side effects. There is no hair loss, no compromise of blood counts, no significant sickness. For me, fatigue may have resulted from this treatment -- but it's unclear to me really whether it was the Herceptin or the two small boys I have living in my house that most contributed to my occasional exhaustion. Regardless, I functioned well while receiving Herceptin for the past year -- and I did not suffer anything more than a twinge of pain when my port was accessed for each treatment. In the short term, I have fared well. In the long term, the jury is still out.

Someone once told me to think of cancer as a chronic condition -- an illness like diabetes or asthma that may linger for life and may require continual treatment. And while battling cancer, perhaps for life, I should just hope that medical advances occur and new treatments become available. And maybe, just maybe, the science of medicine will decrease by leaps and bounds the number of people who die from cancer.

During my own battle with cancer -- which has been 18 months long -- two new breast cancer drugs have hit the scene with rave reviews from researchers and medical professionals. This is good news for me because my type of breast cancer makes me a candidate for both drugs. Herceptin is one of these drugs -- given to women who are HER-2/neu positive -- that's me -- and over express a protein that makes the tumor aggressive. Herceptin is received over 52 weeks -- and I go every three weeks for a 90-minute infusion of this clear liquid that causes me really no side effects at all. It can be toxic to the heart but monitoring tests have revealed that my heart is not suffering at this time. And with just three more infusions to go -- one this Wednesday -- I will likely encounter no adverse reactions to this potentially life-saving drug.

And now Tykerb is making headlines. Tykerb, suggested for use with advanced breast cancer and manufactured by British-based GlaxoSmithKline PLC, is an experimental drug that delays the growth of tumors nearly twice as long as standard chemotherapy in patients who no longer respond to Herceptin. This finding, reported this past Saturday at a meeting in Atlanta of the American Society of Clinical Oncology, confirms initial findings about the promise of this drug -- that like Herceptin, made by Genentech, precisely targets tumors without killing lots of healthy cells. The difference between the two drugs is that Herceptin blocks the protein on the cell's surface and Tykerb does it inside the cell -- blocking a second abnormal protein too. And while Herceptin is given intravenously, Tykerb is given in pill form -- which may make it cheaper and easier to use.

While now part of an international study, Tykerb may be available to women in the United States later this year. And it perhaps will be offered in conjunction with Herceptin or instead of Herceptin for women with advanced breast cancer.

I hope I do not ever need Tykerb -- and that Herceptin alone will be enough for me -- but it is comforting to know that there is something else out there. Something that if necessary, just might help me live with this potentially chronic condition called cancer.

The Chicago Sun-Times is reporting that Roger Ebert, movie critic for the nationally syndicated movie review show Ebert & Roeper, will be having surgery to remove a cancerous growth on his salivary gland. Ebert, who is 63, and a three-time thyroid cancer survivor, is quoted as saying, "This is not considered to be a life-threatening form of cancer, and I expect to make a full recovery. I'll continue to function as a film critic during this time." He doesn't plan on missing any work and will tape shows in advance of his surgery. In the last four years, Ebert has gone through surgery and radiation treatments for thyroid cancer.

Ebert began his career in journalism when, in 1966, the Chicago Sun-Times offered him a features writer position. His unique journalistic style in reviewing movies earned him the first Pulitzer Prize awarded to a film critic. To learn more about the no-holds-barred critic of film, visit the Oral Cancer Foundation famous people profile of Roger Ebert -- cancer survivor.